ClinicalTrials.gg
CompletedNCT02664805Updated Apr 29, 2026

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

A Phase 2 interventional study of LEO 124249 ointment and LEO 124249 ointment vehicle in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
8th of 12
91 · median 178
Started
2016
the only one that year
Phase 2
3 of 13
none open now
Registered
3rd of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2, and was the 3rd registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 67 Eczema studies recruiting now, 31 (46%) set no upper age limit and 28 (42%) stop at 75 or younger; 35 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

To compare the efficacy of twice daily applications of LEO 124249 ointment with LEO 124249 ointment vehicle for up to 8 weeks in the treatment of subjects with chronic hand eczema.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of chronic hand eczema with or without atopic etiology/background with a history of not adequately controlled disease activity with cutaneously applied
  • Physician's Global Assessment of disease severity graded as at least mild at Visit 1
  • In overall good health including well controlled diseases

Exclusion criteria

Exclusion Criteria:

  • Systemic treatment with drugs (e.g. methotrexate, cyclosporine, azathioprine), retinoids (e.g. alitretinoin) or within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).
  • PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4 weeks prior to randomization
  • Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization
  • Concurrent skin diseases on the hands
  • Current diagnosis of exfoliative dermatitis
  • Significant clinical infection (impetiginized hand eczema) on the hands which requires antibiotic treatment
  • A marked abnormal at baseline
  • Known hepatic dysfunction or hepatic dysfunction tested at Screening
  • Current participation in any other interventional clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Active comparator
    LEO 124249 ointment

    Twice daily cutaneous application for 8 weeks

    Drug: LEO 124249 ointment

  • Placebo comparator
    LEO 124249 ointment vehicle

    Twice daily cutaneous application for 8 weeks

    Drug: LEO 124249 ointment vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)

    Treatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear

    Time frame: 56 days

Secondary outcomes

  1. Hand Eczema Severity Index (HECSI) at visit 6

    Time frame: 56 days

  2. Subjects with treatment success according to the Patient's Global Assessment of disease severity (PaGA) at visit 6 (End of Treatment)

    Treatment success according to the PaGA is defined as: Subjects having very mild or mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or very mild

    Time frame: 56 days

07

Study locations

1 site
  • Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Jul 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2016
First posted
Jan 27, 2016
Start
Feb 2016
Primary completionActual
Jul 2016
CompletionActual
Oct 2016
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02664805
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Jan 27, 2016
Start date
Feb 2016
Primary completion
Jul 2016
Completion
Oct 2016
Last update
Apr 29, 2026

Study contacts

Margitta Worm, Prof Dr
principal investigator · Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion